Author

Fernanda B. Musa

Observed name: F.B. Musa

Institution: Swedish Medical Center

Observed institution: Swedish Medical Center

ORCID: 0000-0003-2136-8755

Observed ORCID: 0000-0003-2136-8755

OpenAlex ID: A5067740911

Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial

2025 · Ramez N. Eskander, Michael W. Sill, et al. · Nature Medicine · 100

Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer

2023 · Ramez N. Eskander, Michael W. Sill, et al. · Obstetrical & Gynecological Survey · 6

1122P Phase II open-label multicenter trial of nab-sirolimus + letrozole in advanced/recurrent endometrioid endometrial cancer

2025 · L.E. Dockery, F.B. Musa, et al. · Annals of Oncology

54 Patterns of genomic testing for epithelial ovarian cancer across a large community-based health care network – a real world experience

2022 · Nicole M. Kretzer, Fernanda B. Musa, et al. · Gynecologic Oncology Reports

53 Frequency of homologous recombination deficiency in a large community-based cohort of epithelial ovarian cancer cases

2022 · Nicole M. Kretzer, Fernanda B. Musa, et al. · Gynecologic Oncology Reports

28 Factors impacting genomic testing rates among epithelial ovarian cancer patients across a large community-based healthcare system

2022 · Nicole M. Kretzer, Christopher J. Darus, et al. · Gynecologic Oncology Reports

Works count: 6

Citation count: 106

H-index: 2

I10-index: 1